Treatment of Clostridioides difficile Infection
First-line Therapy
- The American College of Gastroenterology and the Infectious Diseases Society of America recommend Vancomycin 125 mg orally four times daily for 10 days as a first-line option for treating Clostridioides difficile infection in adults, with fidaxomicin 200 mg twice daily for 10 days as an effective alternative 1, 2, 3, 4
- For pediatric patients, vancomycin 10 mg/kg/dose (max 125 mg) four times daily for 10 days is recommended, with fidaxomicin approved for pediatric patients ≥6 months of age for CDI treatment 1, 2
Management of Severe Disease
- Severe CDI is defined by the presence of any of the following: temperature greater than 38.5°C, leukocytosis greater than 15,000/mm³, serum creatinine rise greater than 50% above baseline, pseudomembranous colitis on endoscopy, or signs of severe colitis on imaging 5
- The European Society of Clinical Microbiology and Infectious Diseases and the European Crohn's and Colitis Organisation recommend oral vancomycin 125 mg four times daily for 10 days, with consideration to increase to 500 mg four times daily for severe CDI 4, 6
- Vancomycin 500 mg four times daily orally or via nasogastric tube PLUS metronidazole 500 mg IV three times daily may be considered for severe CDI, with surgical consultation for possible colectomy in cases of perforation, systemic inflammation, toxic megacolon, or severe ileus, and serum lactate > 5.0 mmol/L 5
- Immediate surgical consultation for possible colectomy is recommended for patients with severe Clostridioides difficile infection, with an alternative surgical approach being diverting loop ileostomy with colonic lavage, combined with antibiotic treatment (intracolonic antegrade vancomycin and intravenous metronidazole) 4
Recurrence Prevention and Treatment
- For patients experiencing their first CDI recurrence, fidaxomicin 200 mg twice daily for 10 days or vancomycin in a tapered and pulsed regimen are recommended 1, 2, 4
- For second and subsequent recurrences, vancomycin 125 mg four times daily for 10 days can be followed by either a pulse regimen (125-500 mg/day every 2-3 days) for at least 3 weeks or a tapered regimen: gradually decreasing the dose to 125 mg per day 4
- For multiple recurrences (≥2 recurrences), consider FMT after appropriate antibiotic treatments have been tried, with important safety considerations, including FDA safety alerts documenting transmission of pathogenic E. coli and potential transmission of SARS-CoV-2 through FMT 1, 2, 4
- The European Society of Clinical Microbiology and Infectious Diseases and the European Crohn's and Colitis Organisation strongly recommend fecal microbiota transplantation (FMT) in combination with oral antibiotic treatment for multiple recurrent CDI unresponsive to repeated antibiotic treatment, with success rates of 70-90% 4, 6
- Bezlotoxumab is indicated as adjunctive therapy to reduce CDI recurrence in high-risk patients, including pediatric patients ≥1 year of age 1, 2
General Management
- Discontinuation of the inciting antibiotic as soon as possible is recommended to reduce recurrence risk, and avoidance of antiperistaltic agents and opiates is recommended to prevent worsening of disease 2, 7, 8, 5
- Treatment response should be evaluated after at least 3 days of therapy, with expected improvements in stool frequency and consistency, and complete normalization of bowel habits may take several weeks despite clinical cure 4, 8, 5
- Common mistakes in CDI treatment include using metronidazole as first-line therapy for severe CDI, failure to recognize fulminant CDI requiring urgent intervention and possible surgical consultation, overuse of FMT before trying appropriate antibiotic regimens, not screening FMT donors properly for transmissible pathogens, and inadequate duration of therapy 1, 2, 4